Cargando…
Statement of Retraction: Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648400/ https://www.ncbi.nlm.nih.gov/pubmed/36350994 http://dx.doi.org/10.1080/21655979.2022.2143469 |
| _version_ | 1784827579281178624 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9648400 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Taylor & Francis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96484002023-02-07 Statement of Retraction: Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer Bioengineered Statement of Retraction Taylor & Francis 2022-11-09 /pmc/articles/PMC9648400/ /pubmed/36350994 http://dx.doi.org/10.1080/21655979.2022.2143469 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Statement of Retraction Statement of Retraction: Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer |
| title | Statement of Retraction: Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer |
| title_full | Statement of Retraction: Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer |
| title_fullStr | Statement of Retraction: Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer |
| title_full_unstemmed | Statement of Retraction: Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer |
| title_short | Statement of Retraction: Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer |
| title_sort | statement of retraction: combination therapy with nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer |
| topic | Statement of Retraction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648400/ https://www.ncbi.nlm.nih.gov/pubmed/36350994 http://dx.doi.org/10.1080/21655979.2022.2143469 |